Charles Schweizer

892 citations

24 papers · 703 indexed · h-index 13

Impact in

Reproductive Medicine top 5%
- Ovarian cancer diagnosis and treatment
Oncology top 10%
- CAR-T cell therapy research
- PARP inhibition in cancer therapy
- Pancreatic and Hepatic Oncology Research

Papers in ⓘ

Oncology 12
- Peptidase Inhibition and Analysis 4
- HER2/EGFR in Cancer Research 2
Pulmonary and Respiratory Medicine 7
- Occupational and environmental lung diseases 4
- Pleural and Pulmonary Diseases 2

Co-authors: Susan C. Weil (15 shared papers)Martin D. Phillips (3 shared papers)Raffit Hassan (4 shared papers)Ira Pastan (3 shared papers)Daniel A. Laheru (1 shared paper)Steven J. Cohen (1 shared paper)Elad Sharon (1 shared paper)Ronan J. Kelly (1 shared paper)
Journals: Journal of Clinical Oncology (8 papers)Clinical Cancer Research (3 papers)Investigational New Drugs (1 paper)International Journal of Radiation Oncology*Biology*Physics (1 paper)Lung Cancer (1 paper)
Partner nations: United States Germany United Kingdom

In The Last Decade

Charles Schweizer

21 papers receiving 665 citations

Peers

Countries citing papers authored by Charles Schweizer

Since Specialization

Citations

This map shows the geographic impact of Charles Schweizer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Schweizer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Schweizer more than expected).

Fields of papers citing papers by Charles Schweizer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles Schweizer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Schweizer. The network helps show where Charles Schweizer may publish in the future.

Co-authors

The 25 scholars most cited alongside Charles Schweizer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Charles Schweizer Line = papers co-authored together Charles Schweizer links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 24 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers Clinical Cancer Research ·Raffit Hassan, Steven J. Cohen, Martin D. Phillips, Ira Pastan, Elad Sharon, Ronan J. Kelly, Charles Schweizer, Susan C. Weil, Daniel A. Laheru	2010	160
2	Farletuzumab, a Humanized Monoclonal Antibody against Folate Receptor α, in Epithelial Ovarian Cancer: a Phase I Study Clinical Cancer Research ·Jason Konner, Katherine M. Bell‐McGuinn, Paul Sabbatini, Martee L. Hensley, William P. Tew, Neeta Pandit‐Taskar, Nicholas Vander, Martin D. Phillips, Charles Schweizer, Susan C. Weil, Steven M. Larson, Lloyd J. Old	2010	133
3	A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse Journal of Clinical Oncology ·Ignace Vergote, Deborah K. Armstrong, Giovanni Scambia, Michael Teneriello, Jalid Sehouli, Charles Schweizer, Susan C. Weil, Aristotelis Bamias, Keiichi Fujiwara, Kazunori Ochiai, Christopher Poole, Vera Gorbunova, Wenquan Wang, Daniel J. O’Shannessy, Thomas J. Herzog	2016	114
4	Inhibition of mesothelin–CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy Lung Cancer ·Raffit Hassan, Charles Schweizer, Kun F. Lu, Barbara Schüler, Alan T. Remaley, Susan C. Weil, Ira Pastan	2009	61
5	Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer Gynecologic Oncology ·Kenneth H. Kim, Danijela Jelovac, Deborah K. Armstrong, Benjamin Schwartz, Susan C. Weil, Charles Schweizer, Ronald D. Alvarez	2015	29
6	Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-γ receptor engagement Oncotarget ·J. Bradford Kline, Rina Kennedy, Earl F. Albone, Qimin Chao, Shawn Fernando, Jennifer McDonough, Katherine A. Rybinski, Wenquan Wang, Elizabeth B. Somers, Charles Schweizer, Luigi Grasso, Nicholas C. Nicolaides	2017	24
7	A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer Clinical Cancer Research ·Axel Grothey, Jonathan Strosberg, Lindsay A. Renfro, Herbert I. Hurwitz, John L. Marshall, Howard Safran, Michael J. Guarino, George P. Kim, J. Randolph Hecht, Susan C. Weil, John Heyburn, Wenquan Wang, Charles Schweizer, Daniel J. O’Shannessy, Luis A. Díaz	2017	23
8	A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma Investigational New Drugs ·Sandra P. D’Angelo, Omid Hamid, Ahmad A. Tarhini, Dirk Schadendorf, Bartosz Chmielowski, Frances A. Collichio, Anna C. Pavlick, Karl D. Lewis, Susan C. Weil, John Heyburn, Charles Schweizer, Daniel J. O’Shannessy, Richard D. Carvajal	2017	21
9	Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: Final data from a multicenter phase II study. Journal of Clinical Oncology ·A. J. White, Robert L. Coleman, D. K. Armstrong, D. Glenn, Annette Bicher, Donald Richards, Andreas Schneeweiß, Lloyd J. Old, Charles Schweizer, Susan C. Weil	2010	20
10	FCGR2A and FCGR3A Genotypes Correlate with Farletuzumab Response in Patients with First-Relapsed Ovarian Cancer Exhibiting Low CA125 Cytogenetic and Genome Research ·Wenquan Wang, Elizabeth B. Somers, Erin N. Ross, J. Bradford Kline, Daniel J. O’Shannessy, Charles Schweizer, Susan C. Weil, Luigi Grasso, Nicholas C. Nicolaides	2017	16
11	Correlation of FCGRT genomic structure with serum immunoglobulin, albumin and farletuzumab pharmacokinetics in patients with first relapsed ovarian cancer Genomics ·Daniel J. O’Shannessy, Katie Bendas, Charles Schweizer, Wenquan Wang, Earl F. Albone, Elizabeth B. Somers, Susan C. Weil, Rhonda Meredith, Jason Wustner, Luigi Grasso, Mark Landers, Nicholas C. Nicolaides	2017	15
12	Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer Cancer Chemotherapy and Pharmacology ·Colm Farrell, Charles Schweizer, Jason Wustner, Susan C. Weil, Masayuki Namiki, Tomohisa Nakano, Kenya Nakai, Martin D. Phillips	2012	15
13	Valproic acid in childhood epilepsy: anticonvulsive efficacy in relation to its plasma levels. PubMed ·Ulrich Klotz, Charles Schweizer	1980	15
14	Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in Combination with High Dose Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (PC) International Journal of Radiation OncologyBiologyPhysics ·Sarah E. Hoffe, Jessica M. Frakes, Todd A. Aguilera, Brian G. Czito, Manisha Palta, Melissa Brookes, Charles Schweizer, Lauren E. Colbert, Shalini Moningi, Manoop S. Bhutani, Shubham Pant, C.W. Tzeng, Rebecca S. Tidwell, Peter F. Thall, Ying Yuan, Elizabeth Charlotte Moser, Jon Holmlund, Joseph M. Herman, Cullen M. Taniguchi	2020	12
15	CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients Cancer Biology & Therapy ·Nicholas C. Nicolaides, Charles Schweizer, Elizabeth B. Somers, Wenquan Wang, Shawn Fernando, Erin N. Ross, Luigi Grasso, Raffit Hassan, J. Bradford Kline	2018	11
16	Sputum cytology of metastatic carcinoma of the lung. PubMed ·William H. Kern, Charles Schweizer	1977	11
17	Amatuximab, a chimeric monoclonal antibody to mesothelin, in combination with pemetrexed and cisplatin in patients with unresectable pleural mesothelioma: Results of a multicenter phase II clinical trial. Journal of Clinical Oncology ·Raffit Hassan, Thierry Jahan, Hedy L. Kindler, Lyudmila Bazhenova, Martin Reck, Ira Pastan, A.J. Ellis, P. Fatato, John Heyburn, Charles Schweizer, Jeff Parno, Bruce A. Wallin	2012	9
18	A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of farletuzumab (MORAb-003) in combination with weekly paclitaxel in subjects with platinum-resistant or refractory relapsed ovarian cancer. Journal of Clinical Oncology ·L. Elit, Jason Konner, D. K. Armstrong, Martin Buck, Andrew Dean, N. Finkler, Ann-Marie Hulstine, Charles Schweizer, M. Phillips, Susan C. Weil	2010	5
19	A first-in-human phase I study of MORAb-004 (MOR4), a humanized monoclonal antibody recognizing TEM-1 (endosialin), in patients with solid tumors. Journal of Clinical Oncology ·Richard D. Carvajal, Mrinal M. Gounder, Christina Coughlin, Jean Fishel, John Heyburn, Daniel J. O’Shannessy, Luigi Grasso, Charles Schweizer, J. Parno, Lloyd J. Old, Nilofer S. Azad, L. A. Diaz	2011	3
20	Die Wirkung von herbiziden auf das sporulierungsvermögen des blattlauspathogenen PilzesErynia neoaphidis Journal of Pest Science ·Saskia Keller, Charles Schweizer	1991	2

About Charles Schweizer

Charles Schweizer is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging, Reproductive Medicine and Biotechnology, having authored 24 papers that have together received 703 indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (6 papers), Monoclonal and Polyclonal Antibodies Research (6 papers), Cancer Research and Treatments (4 papers), Occupational and environmental lung diseases (4 papers), Peptidase Inhibition and Analysis (4 papers), Pleural and Pulmonary Diseases (2 papers), Galectins and Cancer Biology (2 papers) and HER2/EGFR in Cancer Research (2 papers). The work is most often cited by research in Reproductive Medicine (170 citations), Oncology (332 citations), Immunology (157 citations), Biotechnology (64 citations) and Pulmonary and Respiratory Medicine (208 citations). Charles Schweizer has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Susan C. Weil, Martin D. Phillips, Raffit Hassan, Ira Pastan, Daniel A. Laheru, Steven J. Cohen, Elad Sharon, Ronan J. Kelly, Wenquan Wang and Daniel J. O’Shannessy. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Investigational New Drugs, International Journal of Radiation Oncology*Biology*Physics and Lung Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact